GSK Executives Visit China’s Ministry of Science and Technology To Discuss Biotech Plans
This article was originally published in PharmAsia News
Executive Summary
Liu Yan-Hua, vice minister of China's Ministry of Science and Technology, recently met top executives from GSK, including Abbas Hussain, President of Emerging Markets, and Jean Stéphenne, President and General Manager of GSK Biologicals. China's investment in biotechnology R&D, which includes biopharmaceuticals, will reach RMB 10 billion under its Eleventh Five-Year Plan (2006-2011). The Ministry of Science and Technology encourages MNCs to collaborate in these R&D plans, with the aim of developing drugs that guarantee quality and affordability for China's large population with diverse economic levels. GSK is planning to invest in vaccine R&D and introduce adjuvant technology for influenza vaccine and cervical cancer vaccine to the country. (Click here for more - Chinese language)